INTERRELATION OF COVID-19 AND HYPERTENSION; A REVIEW STUDY

dc.contributor.authorSaleha Haidari
dc.contributor.authorZahra Rahimi
dc.contributor.authorSayed Muslim Musavi
dc.contributor.authorMarina Hakimi
dc.date.accessioned2025-12-31T15:37:38Z
dc.date.issued2023-06-21
dc.description.abstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory tract virus that causes Coronavirus disease (COVID-19). The virus originated in Wuhan, China, in December 2019 and has spread to the world. Most patients reported having at least one comorbidities with COVID-19 upon hospital admission. Hypertension, diabetes, chronic obstructive pulmonary disease, obesity, and cardiovascular diseases are among the most commonly reported. Comorbidities are contributing to acute disease prognosis and increased risk of severe symptoms. This review intends to understand how hypertension affect the disease’s prognosis and how severe the outcome can be expected
dc.formatapplication/pdf
dc.identifier.urihttps://scholarexpress.net/index.php/wbph/article/view/2933
dc.identifier.urihttps://asianeducationindex.com/handle/123456789/49422
dc.language.isoeng
dc.publisherScholar Express Journals
dc.relationhttps://scholarexpress.net/index.php/wbph/article/view/2933/2519
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourceWorld Bulletin of Public Health; Vol. 23 (2023): WBPH; 164-172
dc.source2749-3644
dc.subjectSARS-CoV-2
dc.subjectHypertension
dc.subjectRAAS inhibitors
dc.titleINTERRELATION OF COVID-19 AND HYPERTENSION; A REVIEW STUDY
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Article

item.page.files

item.page.filesection.original.bundle

pagination.showing.labelpagination.showing.detail
loading.default
thumbnail.default.alt
item.page.filesection.name
haidari_2023_interrelation_of_covid-19_and_hypertensi.pdf
item.page.filesection.size
210.47 KB
item.page.filesection.format
Adobe Portable Document Format

item.page.collections